MIRA INFORM REPORT

 

 

Report No. :

322205

Report Date :

15.05.2015

 

IDENTIFICATION DETAILS

 

Name :

MAJAL PHARMACEUTICAL CO

 

 

Registered Office :

Zahran Plaza, 2nd Floor, Office No. 203, Zahran Street, PO Box 142907, Amman 11844

 

 

Country :

Jordan

 

 

Financials (as on) :

31.12.2014

 

 

Date of Incorporation :

03.06.2010

 

 

Com. Reg. No.:

1617

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Engaged in the manufacture of pharmaceuticals.

 

 

No. of Employees :

65

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Jordan

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

JORDAN - ECONOMIC OVERVIEW

 

Jordan's economy is among the smallest in the Middle East, with insufficient supplies of water, oil, and other natural resources underlying the government's heavy reliance on foreign assistance. Other economic challenges for the government include chronic high rates of poverty, unemployment, inflation, and a large budget deficit and resulting government debt. King ABDALLAH during the 2000s implemented significant economic reforms, such as opening the trade regime and privatizing state-owned companies, that attracted foreign investment and contributed to average annual economic growth of 8% for 2004 through 2008. The global economic slowdown and regional turmoil since, however, reduced the average annual growth rate to 2.6% for the 2010-2013 period and hurt export-oriented sectors, construction, and tourism. Jordan's finances have been strained by a series of natural gas pipeline attacks in Egypt, causing Jordan to substitute more expensive diesel imports, primarily from Saudi Arabia, to generate electricity. To diversify its energy mix, Jordan is currently exploring nuclear power generation, exploitation of abundant oil shale reserves and renewable technologies, as well as the import of Israeli offshore gas. In August 2012, to correct budgetary and balance of payments imbalances, Jordan entered into a $2.1 billion, three year International Monetary Fund Stand-By Arrangement. In 2014, fiscal reform measures enacted in the previous few years continued to boost government revenues and reduced the budget deficit even as an influx of over 620,000 Syrian refugees since 2011 put additional pressure on expenditures.

 

Source : CIA


SUMMARY

 

Company Name                                    : MAJAL PHARMACEUTICAL CO

Country of Origin                                   : Jordan

Legal Form                                           : Limited Liability Company

Registration Date                                  : 3rd June 2010

Commercial Registration Number           : 1617, Amman

Membership Number                             : 162541

Issued Capital                                       : JD 100,000

Paid up Capital                                     : JD 100,000

Total Workforce                         : 65

Activities                                               : Manufacturers of pharmaceuticals

Financial Condition                                : Fair

Payments                                             : Nothing detrimental uncovered

Operating Trend                                    : Steady

Person Interviewed                                : Nada Daana, Financial Controller


COMPANY NAME

 

MAJAL PHARMACEUTICAL CO

 

 

ADDRESS

 

Registered & Physical Address

 

Building                        : Zahran Plaza, 2nd Floor, Office No. 203

Street               : Zahran Street

PO Box            : 142907

Town                : Amman 11844

Country : Jordan

Telephone         : (962-6) 5810703 / 5827999 / 5810727

Facsimile          : (962-6) 5820876

Mobile              : (962-79) 6679977        

Email                : mr.odat@yahoo.com / nada.daana@mspharma.com

 

Premises

 

Subject operates from a medium sized suite of offices that are rented and located in the Central Business Area of Amman.

 

 

KEY PRINCIPALS

 

Name                                                                                       Position

 

Ghaith Munir Sukhtain                                                                Managing Director

 

Ghassan Aqeel Sukhtain                                                            Director

 

Munjed Sukhtain                                                                        Director

 

Emaad Qaqaish                                                                        Chief Financial Officer

 

Nada Daana                                                                              Financial Controller

 

 

LEGAL FORM & OWNERS

 

Date of Establishment  : 3rd June 2010

 

Legal Form                  : Limited Liability Company

 

Commercial Reg. No.   : 1617, Amman

 

Membership No.           : 162541

 

Issued Capital              : JD 100,000

 

Paid up Capital            : JD 100,000

 

Name of Shareholder (s)                                                    

 

Ghaith Munir Sukhtain                                                                           

 

Ghassan Aqeel Sukhtain                                                                                   

 

Munjed Sukhtain

 

Al Maseera International Co

Amman

 

 

AFFILIATED COMPANIES

 

Amana Tourism Services

 

Arabian Office Automation Company Ltd

 

Beit Jala Pharmaceutical Manufacturing (BJP)

 

Exir LLC

 

Ghayat Construction

 

Households & Toiletries Manufacturing Co

 

Jordan Greenhouses Manufacturing Co Ltd (Rayyan)

 

Munir Sukhtian Global

 

Munir Sukhtian Investment

 

Munir Sukhtian Trading Group Co Ltd

 

Sukhtian Brothers

 

Sukhtian Industrial Trading (SIT)

 

Tabuk Pharmaceutical Manufacturing Company

 

United Pharmaceuticals Manufacturing Co Ltd (UPM)

OPERATIONS

 

Activities: Engaged in the manufacture of pharmaceuticals.

 

Import Countries: Europe and the Far East

 

Operating Trend: Steady

 

Subject has a workforce of 65 employees.

 

 

FINANCIAL DATA

 

Financial highlights provided by local sources are given below:

 

Currency: Jordanian Dinars (JD)

 

                                                Year Ending 31/12/13:              Year Ending 31/12/14:

 

Total Sales                                JD 3,100,000                             JD 3,450,000

 

Local sources consider subject’s financial condition to be Fair.

 

The above financial figures are based on estimations by our local sources.

 

 

BANKERS

 

Arab Jordan Investment Bank

Ibn Hani Street

Shmeisani

PO Box: 8797

Amman 11121

Tel: (962-6) 5607126 / 5607138

Fax: (962-6) 5681482 / 5690646

 

 

PAYMENT HISTORY

 

No complaints regarding subject’s payments have been reported.

 


GENERAL COMMENTS

 

During the course of this investigation nothing detrimental was uncovered regarding subject’s operating history or the manner in which payments are fulfilled. As such the company is considered to be a fair trade risk.

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.84

UK Pound

1

Rs.100.65

Euro

1

Rs.72.88

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

TPT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.